Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06489964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates: Mar 2026 to Dec 2026
    • Start date changed from estimate of Dec 2025 to Oct 23, 2025
    v4
  2. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 8 more changesShow less
    • Start date: Apr 2025 to Dec 2025
    • Primary endpoints revised (2)
    • Study sites: 1 to 2
    • Interventions: Transitional Stepped Co-payment Model - Step 1 (Other), Transitional Stepped Co-payment Model - Step 2 (Other), Transitional Stepped… to Co-payment Model - Step 1 (Other), Co-payment Model - Step 2 (Other), Co-payment Model - Step 3 (Other), Co-payment Model - Step 4 (Other)
    • Eligibility criteria expanded, about 567 words
    • Secondary endpoint revised
    • Study description expanded, about 21 words
    • Collaborators: 2 to 4
  3. Notable Primary completion date: Mar 2025 to Mar 2026
    • Start date: Sep 2024 to Apr 2025
    v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this pilot demonstration and evaluation project is to determine the acceptability and feasibility of a co-payment model among the public and providers and assess whether a co-payment model in community pharmacies in Nova Scotia and Ontario increases the accessibility and uptake of recommended but unfunded vaccines. The research questions that guided the development of this study are: * What is the feasibility of implementing a co-payment model for recommended but unfunded vaccines in community pharmacies? * To what extent is a co-payment model for recommended but unfunded vaccines perceived as acceptable to community pharmacists and the public? A co-payment model will be piloted at a maximum of 8 select community pharmacy sites in Nova Scotia (n=4 sites) and Ontario (n=4 sites). Each community pharmacy site will be randomly assigned to pilot one of the steps of the co-payment model for the duration of the demonstration project. At the end of the pilot study, participating pharmacy providers will be asked to complete an online survey about their experiences in implementing the co-payment model into their pharmacy. As part of the co-payment model, recruited members of the public (participants) will choose to receive the vaccine (if eligible) at a reduced cost either for themselves or their dependent (e.g., incapable minor or adult), as part of routine care (following standard pharmacy practice). After receiving the vaccine, the participant will complete an online survey exploring their thoughts on the co-payment model, their satisfaction with the co-payment model, their perception on vaccines in general, and their demographics (such as gender, age, education, race/ethnicity).
Trial Details
NCT Number NCT06489964
Lead Sponsor Canadian Immunization Research Network
Collaborators: Dalhousie University, AstraZeneca, GlaxoSmithKline, Canadian Center for Vaccinology
Conditions
(from sponsor)
Preventable Disease, Vaccine
Related terms Vaccine-Preventable Diseases
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov